ALTEOGEN (KOSDAQ:A196170) - Share price, News & Analysis

A196170 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

A196170 Stock Overview

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.

Rewards

Earnings are forecast to grow 65.8% per year

Risk Analysis

No risks detected for A196170 from our risk checks.

ALTEOGEN Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ALTEOGEN
Historical stock prices
Current Share Price	₩47,600.00
52 Week High	₩99,000.00
52 Week Low	₩45,900.00
Beta	0.94
1 Month Change	-8.46%
3 Month Change	-1.45%
1 Year Change	-33.05%
3 Year Change	228.28%
5 Year Change	953.88%
Change since IPO	1,228.37%

Recent News & Updates

Apr 13

ALTEOGEN Inc.'s (KOSDAQ:196170) Has Found A Path To Profitability

We feel now is a pretty good time to analyse ALTEOGEN Inc.'s ( KOSDAQ:196170 ) business as it appears the company may...

Shareholder Returns

	A196170	KR Biotechs	KR Market
7D	-13.0%	-4.1%	-3.3%
1Y	-33.1%	-34.3%	-14.3%

Return vs Industry: A196170 exceeded the KR Biotechs industry which returned -34.3% over the past year.

Return vs Market: A196170 underperformed the KR Market which returned -14.3% over the past year.

Price Volatility

Is A196170's price volatile compared to industry and market?
A196170 volatility
A196170 Average Weekly Movement	7.2%
Biotechs Industry Average Movement	6.5%
Market Average Movement	5.5%
10% most volatile stocks in KR Market	10.4%
10% least volatile stocks in KR Market	3.1%

Stable Share Price: A196170 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: A196170's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2008	98	Soon-Jae Park	https://www.alteogen.com

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology.

ALTEOGEN Fundamentals Summary

How do ALTEOGEN's earnings and revenue compare to its market cap?
A196170 fundamental statistics
Market Cap	₩2.13t
Earnings (TTM)	-₩3.88b
Revenue (TTM)	₩41.12b

49.4x

P/S Ratio

-523.3x

P/E Ratio

Is A196170 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
A196170 income statement (TTM)
Revenue	₩41.12b
Cost of Revenue	₩33.04b
Gross Profit	₩8.08b
Other Expenses	₩11.96b
Earnings	-₩3.88b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-90.97
Gross Margin	19.64%
Net Profit Margin	-9.43%
Debt/Equity Ratio	1.4%

How did A196170 perform over the long term?

See historical performance and comparison

Valuation

Is ALTEOGEN undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

14.88x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A196170's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A196170's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: A196170 is unprofitable, so we can't compare its PE Ratio to the KR Biotechs industry average.

PE vs Market: A196170 is unprofitable, so we can't compare its PE Ratio to the KR market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A196170's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: A196170 is overvalued based on its PB Ratio (14.9x) compared to the KR Biotechs industry average (3.4x).

Future Growth

How is ALTEOGEN forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

65.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A196170 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).

Earnings vs Market: A196170 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: A196170's is expected to become profitable in the next 3 years.

Revenue vs Market: A196170's revenue (34.9% per year) is forecast to grow faster than the KR market (9.7% per year).

High Growth Revenue: A196170's revenue (34.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A196170's Return on Equity is forecast to be low in 3 years time (13.6%).

Past Performance

How has ALTEOGEN performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-3.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A196170 is currently unprofitable.

Growing Profit Margin: A196170 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: A196170 is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.

Accelerating Growth: Unable to compare A196170's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A196170 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20.1%).

Return on Equity

High ROE: A196170 has a negative Return on Equity (-3.76%), as it is currently unprofitable.

Financial Health

How is ALTEOGEN's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: A196170's short term assets (₩212.2B) exceed its short term liabilities (₩12.4B).

Long Term Liabilities: A196170's short term assets (₩212.2B) exceed its long term liabilities (₩3.2B).

Debt to Equity History and Analysis

Debt Level: A196170 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if A196170's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A196170 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: A196170 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 22.2% each year

Dividend

What is ALTEOGEN current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A196170's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A196170's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A196170's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A196170's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A196170 has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

0.3yrs

Average management tenure

CEO

Soon-Jae Park

no data

Tenure

Dr. Soon-Jae Park, Ph D., serves as the Chief Executive Officer of ALTEOGEN Inc. He has several years of experience in R&D of biomedicine. He served as the Executive Officer at BINEX Co., Ltd.He started w...

Leadership Team

Experienced Management: A196170's management team is not considered experienced ( 0.3 years average tenure), which suggests a new team.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/12 00:00
End of Day Share Price	2022/05/12 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31